CVS Health Corporation $CVS Stock Acquired by Intech Investment Management LLC

Intech Investment Management LLC boosted its position in CVS Health Corporation (NYSE:CVS – Free Report) by 184.1% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 151,876 shares of the pharmacy operator’s stock after purchasing an additional 98,422 shares during the quarter. Intech Investment Management LLC’s holdings in CVS Health were worth $13,014,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Cetera Trust Company N.A raised its stake in shares of CVS Health by 1.2% during the third quarter. Cetera Trust Company N.A now owns 17,775 shares of the pharmacy operator’s stock valued at $1,523,000 after purchasing an additional 207 shares in the last quarter. White Pine Capital LLC bought a new position in CVS Health in the 3rd quarter valued at about $205,000. Bessemer Group Inc. grew its position in CVS Health by 26.2% in the 3rd quarter. Bessemer Group Inc. now owns 49,568 shares of the pharmacy operator’s stock valued at $4,249,000 after buying an additional 10,298 shares in the last quarter. Virtus Advisers LLC increased its stake in CVS Health by 72.4% during the 3rd quarter. Virtus Advisers LLC now owns 1,686 shares of the pharmacy operator’s stock valued at $144,000 after buying an additional 708 shares during the period. Finally, AlTi Global Inc. increased its stake in CVS Health by 10.3% during the 3rd quarter. AlTi Global Inc. now owns 5,150 shares of the pharmacy operator’s stock valued at $441,000 after buying an additional 483 shares during the period. 80.66% of the stock is owned by institutional investors and hedge funds.

Latest CVS Health News

Investors following CVS have been watching these news items:

  • Positive Sentiment: CVS raised its 2026 adjusted EPS outlook to at least $8.20 and plans to separate into two publicly traded companies, developments that could support investor confidence in its earnings and strategic plans. CVS Health: 3 Key Takeaways for Long-Term Investors
  • Neutral Sentiment: CVS’s analysis found GLP-1 medicines improve patient outcomes, but their drug costs currently outweigh associated healthcare savings. The drugs could reach a break-even point for employers at prices of about $350 per month or less. Lower prices could improve affordability and expand use, though the findings also highlight the gap between current costs and long-term savings. CVS Health Study Finds GLP-1 Medicines Improve Outcomes But Drug Costs Still Outweigh Savings
  • Neutral Sentiment: Royal Bank of Canada lowered its CVS price target from $113 to $108 but maintained an “outperform” rating, leaving its target above the stock’s recent trading level. Royal Bank of Canada stock recommendations

Analyst Ratings Changes

CVS has been the topic of a number of recent analyst reports. Barclays dropped their price target on shares of CVS Health from $108.00 to $107.00 and set an “overweight” rating on the stock in a research report on Thursday, November 5th. TD Cowen reiterated a “buy” rating on shares of CVS Health in a report on Wednesday, November 4th. Leerink Partners lowered their price objective on shares of CVS Health from $112.00 to $104.00 and set an “outperform” rating on the stock in a research note on Thursday, November 5th. Cantor Fitzgerald restated a “neutral” rating on shares of CVS Health in a research report on Friday, October 9th. Finally, Wall Street Zen lowered CVS Health from a “strong-buy” rating to a “buy” rating in a research note on Monday, October 19th. Twenty-three investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $107.33.

View Our Latest Analysis on CVS

CVS Health Stock Performance

CVS opened at $88.50 on Tuesday. The firm has a market cap of $113.23 billion, a PE ratio of 10.78, a P/E/G ratio of 0.78 and a beta of 0.58. The company has a quick ratio of 0.66, a current ratio of 0.85 and a debt-to-equity ratio of 0.71. The business has a fifty day simple moving average of $89.48 and a 200-day simple moving average of $89.16. CVS Health Corporation has a fifty-two week low of $69.51 and a fifty-two week high of $110.68.

CVS Health (NYSE:CVS – Get Free Report) last announced its earnings results on Wednesday, November 4th. The pharmacy operator reported $2.09 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.65 by $0.44. CVS Health had a return on equity of 13.65% and a net margin of 2.62%. The company had revenue of $108.40 billion for the quarter, compared to analyst estimates of $104.72 billion. During the same period in the previous year, the firm earned $1.60 earnings per share. CVS Health’s revenue for the quarter was up 5.4% compared to the same quarter last year. As a group, equities analysts predict that CVS Health Corporation will post 8.26 EPS for the current fiscal year.

CVS Health Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Monday, November 2nd. Investors of record on Thursday, October 22nd were paid a $0.6650 dividend. The ex-dividend date of this dividend was Thursday, October 22nd. This represents a $2.66 dividend on an annualized basis and a yield of 3.0%. CVS Health’s dividend payout ratio (DPR) is currently 30.97%.

Insider Transactions at CVS Health

In related news, EVP Prem Shah acquired 23,855 shares of the business’s stock in a transaction on Friday, November 6th. The shares were purchased at an average price of $83.89 per share, for a total transaction of $2,001,195.95. Following the acquisition, the executive vice president owned 88,516 shares in the company, valued at approximately $7,425,607.24. This represents a 36.89% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.85% of the company’s stock.

About CVS Health

(Free Report)

CVS Health is a U.S.-based health care company that operates retail pharmacies, provides pharmacy benefit management services, and offers health insurance and other health services. Its businesses include CVS Pharmacy, pharmacy benefit manager CVS Caremark, and Aetna, its health benefits division. The company also provides care through MinuteClinic walk-in clinics and health care businesses including Oak Street Health and Signify Health. Its services span prescription fulfillment, pharmacy benefit management, health insurance, primary care, and in-home and community-based care.

Featured Articles

Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corporation (NYSE:CVS – Free Report).

Institutional Ownership by Quarter for CVS Health (NYSE:CVS)

Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.